Cargando…
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies (BRAFi) is a major challenge and limits their efficacy. We have previously shown that the BRAF(V600E) signaling pathway mediates the expression of...
Autores principales: | Uebel, Anne, Kewitz-Hempel, Stefanie, Willscher, Edith, Gebhardt, Kathleen, Sunderkötter, Cord, Gerloff, Dennis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916477/ https://www.ncbi.nlm.nih.gov/pubmed/36768289 http://dx.doi.org/10.3390/ijms24031963 |
Ejemplares similares
-
BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma
por: Gebhardt, Kathleen, et al.
Publicado: (2021) -
Comprehensive Analyses of miRNAs Revealed miR-92b-3p, miR-182-5p and miR-183-5p as Potential Novel Biomarkers in Melanoma-Derived Extracellular Vesicles
por: Gerloff, Dennis, et al.
Publicado: (2022) -
Melanoma-Derived Exosomal miR-125b-5p Educates Tumor Associated Macrophages (TAMs) by Targeting Lysosomal Acid Lipase A (LIPA)
por: Gerloff, Dennis, et al.
Publicado: (2020) -
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021) -
SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters
por: Groß, Elisabeth, et al.
Publicado: (2023)